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Abstract Mannose-binding protein (MBP) belongs to the 
collectin subgroup of C-type lectins with specificity for mannose 
and N-acetyiglucosamine sugars. We investigated whether rat 
MBPs isolated from serum (S-MBP) and liver (L-MBP) interact 
with phospholipids using antibody against each MBP. Both S- 
and L-MBPs bound to phosphatidylinositol coated onto micro- 
titer wells in a concentration- and a Ca2+-dependent manner. L- 
MBP also bound to phosphatidyiglycerol and weakly to 
phosphatidylserine. MBPs interacted with liposomes composed 
of these lipids. S- and L-MBPs bound to phosphatidylinositol 4-
monophosphate. L-MBP also bound to cardiolipin. These results 
provide evidence for a novel type of ligand binding specificity for 
MBPs, and raise the possibility that phospholipids are ligands for 
collectins. 
© 1997 Federation of European Biochemical Societies. 
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colipids containing the trlmannosyl core of complex N-linked 
oligosaccharides [7]. SP-A binds to galactosylceramide, lacto- 
sylceramide and asialo-GM2 [8,9]; SP-D binds to glucosylcer- 
amide [10], Lung surfactant lectins are also unique phospho- 
lipid-binding proteins; SP-A binds to phosphatidylcholine 
(PC) and sphingomyelin with the highest affinity for dipalmi- 
toyl species of PC [11], which is an essential lipid component 
of surfactant o reduce surface tension i the air-liquid inter- 
face; SP-D binds to phosphatidylinositol [12]. The CRDs of 
C-type lectins are characterized by 14 invariant and 18 highly 
conserved amino acid residues [13]. The strong sequence con- 
servation in the CRD, and the similarities in carbohydrate 
binding specificity and oligomeric structure among collectins 
[14] may suggest that these lectins are functionally homolo- 
gous. In this study we investigated whether MBPs isolated 
from serum and liver of rats bind to certain phospholipids. 
We here report evidence for a novel type of binding specificity 
for MBPs to phospholipids. 
1. Introduction 
2. Materials and methods 
Mannose-binding protein (MBP) is a C-type lectin with 
specificity for mannose and N-acetylglucosamine sugars [1]. 
MBP belongs to the collectin subgroup of C-type lectins, 
which also includes pulmonary surfactant proteins SP-A and 
SP-D [2]. The collectins share a common structural domain 
arrangement: a cysteine-containing amino terminus; a colla- 
gen-like domain; a neck domain; and a carbohydrate recog- 
nition domain (CRD). MBP is believed to play important 
roles in the innate immune system, which is critical in the first 
line of host defense. Two rat MBPs, MBP-A and MBP-C, 
have been characterized and are homologous to each other 
with 56% sequence identity [3]. MBP-A appears to be a pre- 
dominant form of serum MBP in rat. MBP-C is a hepatic 
lectin. Serum MBPs isolated from rat, human and rabbit ac- 
tivate the classical complement pathway [4], referred to as a 
lectin pathway, which may be associated with bactericidal 
activity and opsonization. C-type lectins have been shown to 
bind to certain glycosphingolipids; human MBP binds to N- 
acetylglucosamine-terminated glycosphingolipids [5]; rat 
MBP-A also binds neoglycolipids containing terminal N-ace- 
tylglucosamine r sidues [6], whereas rat MBP-C binds neogly- 
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2.1. Isolation oj mannose-binding proteins jrom rats 
Serum mannose-binding protein (S-MBP) was isolated from sera of 
Sprague-Dawley rats by the method of Kozutsumi et al. [15]. Briefly, 
the pooled rat sera were mixed with an equal volume of 40 mM Tris 
buffer (pH 7.4) containing 2.5 M NaCI and 40 mM CaCI=,. After 
incubation for 2 h at 4°C, the sera was centrifuged at 10000×g~,, 
for 10 min. The supernatant was then applied to an affinity column 
of mannose-Sepharose 6B (5 ml bed volume/100 ml serum) that had 
been equilibrated with 20 mM Tris buffer (pH 7.4) containing 1.25 M 
NaC1 and 20 mM CaC12 (binding buffer). After the colunm had been 
washed with the binding buffer, the proteins binding to the affinity 
matrix were eluted with 20 mM Tris buffer (pH 7.4) containing 1.25 
M NaC1 and 2 mM EDTA. The Ca 2+ concentration of the eluate was 
adjusted to 20 mM by the addition of 1 M CaCI2, and the eluate was 
applied to the second small column (2 ml bed volume/100 ml serum) 
of mannose-Sepharose 6B. The column was washed with 20 mM Tris 
buffer (pH 7.4) containing 0.15 M NaCI and 2 mM CaCI~. The MBP 
binding to the affinity matrix was finally eluted with 20 mM Tris 
buffer (pH 7.4) containing 0.15 M NaC1 and 2 mM EDTA. The 
purified S-MBP was then dialyzed against 20 mM Tris buffer (pH 
7.4) containing 0.15 M NaC1. 
Liver mannose-binding protein (L-MBP) was isolated from rat liver 
by the method of Mizuno et al. [16]. Briefly, rat liver was minced and 
blended with cold acetone. After drying the cake, acetone powder was 
suspended in 10 volumes of 20 mM imidazole (pH 7.8) containing 0.4 
M KC1, 0.5 mM EDTA and 2%, Triton X-100 (extracting buffer) and 
centrifuged at 12 000 Xg~,, for 15 rain. The supernatant was combined 
with the affinity gel of mannose-Sepharose 6B (100 ml gel/100 g liver) 
and the suspension was adjusted to 5 mM CaCl~ by adding I M 
CaCI2. After stirring for 60 min at 4°C, the gel was sedimented by 
centrifugation at 200xg for 10 rain and washed several times with 20 
mM imidazole (pH 7.8) containing 1.25 M NaCI, 5 mM CaCI2 and 
0.5% Triton X-100 (washing buffer), and poured into a column. The 
proteins binding to the affinity gel were eluted with 20 mM imidazole 
(pH 7.8) containing 1.25 M NaC1, 2 mM EDTA and 0.5% Triton X- 
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100 (eluting buffer). After the eluate was adjusted to a concentration 
of 20 mM Ca 2+ by the addition of 1 M CaC12, the affinity chroma- 
tography was repeated with e washing and eluting buffer containing 
a lower concentration of Triton X-100 (0.1%) using a smaller column 
(10 ml gel). The affinity chromatography was repeated once more 
using a column of 5 ml gel. The purified L-MBP was passed through 
a column of Extracti-Gel (Pierce) to remove detergent. The protein 
was finally dialyzed against 20 mM Tris buffer (pH 7.4) containing 
0.15 M NaC1. 
Lung surfactant lectins SP-A and SP-D were purified from rat lung 
lavage by the method described previously [11,12]. 
2.2. Preparation of polyclonal antibodies and enzyme-linked 
immunosorbent assay 
Purified S-MBP and L-MBP (100 gg protein each) were emulsified 
with Freund's complete adjuvant and injected into New Zealand 
White rabbits intramuscularly. For boost immunization, MBP with 
Freund's incomplete adjuvant and MBP alone were injected on day 14 
and day 28, respectively. Eight days after the last immunization, the 
rabbits were bled and antisera were obtained. The IgG fraction of 
antiserum against each protein was purified by an affinity column of 
protein A-Sepharose CL 4B (Pharmacia Fine Chemicals). 
A sandwich enzyme-linked immunosorbent assay (ELISA) for each 
MBP was developed. IgG was conjugated with horseradish peroxidase 
(HRP) using periodate oxidation by the method of Ishikawa et al. 
[17]. The microtiter wells were coated with anti-MBP IgG (20 lag/ml in 
0.1 M NaHCO3, 100 gl/well) at 4°C overnight and the wells were 
incubated with phosphate buffered saline (PBS) containing 3% (w/v) 
skim milk and 0.1% (v/v) Triton X-100 (buffer A) to block the non- 
specific binding. After blocking, 50 gl of samples and purified MBP as 
standards were incubated at 37°C for 60 rain, and then incubated with 
anti-MBP IgG-HRP conjugate, o-Phenylenediamine was used as the 
substrate for the peroxidase reaction. After stopping the reaction by 
the addition of 2 M sulfuric acid, absorbance at490 nm was measured 
in a immunoreader. The ELISA was able to detect MBP at levels 
ranging from 3 to 200 ng/ml. 
2.3. Phospholipids 
Phosphatidylinositol (PI) from bovine liver, phosphatidylinositol 4- 
monophosphate (PIP) from bovine brain, phosphatidylinositol 4,5-di- 
phosphate (PIP2) from bovine brain, phosphatidylglycerol from egg 
yolk, sphingomyelin (SM) from egg yolk, phosphatidylserine (PS) 
from bovine brain, phosphatidylethanolamine (PE) from bovine liver, 
cardiolipin from bovine heart, phosphatidylcholine (PC) from egg 
yolk and dipalmitoylphosphatidylcholine (DPPC) were purchased 
from Sigma. 
2.4. Binding of MBPs to phospholipids coated on microtiter wells 
Phospholipids (1 lag in 20 gl ethanol/well) were put into microtiter 
wells (Dynatech Laboratories, Inc.) and air-dried. The wells were in- 
cubated with 300/al of 50 mM Tris buffer (pH 7.4) containing 0.1 M 
NaCI, 2 mM CaC12 and 20 mg/ml bovine serum albumin (buffer B) 
for 30 min to block nonspecific binding. 50 lal of L-MBP or S-MBP 
(1-10 gg/ml) in buffer B was added to the wells and incubated for 60 
min at room temperature. The wells were then washed with 300 lal of 
the buffer B three times. The MBP binding to the lipids was detected 
using antibody (20 lag/ml in buffer A) against each protein, followed 
by incubation with HRP-labeled anti-rabbit IgG (Bio-Rad). After 
washing the wells with PBS containing 0.1% (v/v) Triton X-100, the 
substrate reaction was performed using o-phenylenediamine and ab- 
sorbance at 490 nm was measured. In some experiments, various 
concentrations of Ca 2+ or Mg 2+, monosaccharide (10 or 100 mM), 
phospholipid liposomes (500 gM), or anti-MBP antibody (10 or 100 
gg/ml) were included when MBPs were incubated with solid phase 
phospholipids. 
2.5. Binding of MBPs to phospholipid liposomes 
The binding of MBPs to multilamellar liposomes composed of PI, 
PG, PS or PC was performed by the sedimentation method with a 
minor modification, as described previously [18]. To prepare multi- 
lamellar liposomes, the lipid was dried under nitrogen and hydrated in 
20 mM Tris buffer (pH 7.4) containing 0.I M NaC1 at 37°C for 1 h 
and then vortexed vigorously for 5 min. The multilamellar liposomes 
(100 gg) and the protein solution (0.2 lag protein/tube) in 20 mM Tris 
buffer (pH 7.4) containing 0.15 M NaC1, 5 mM CaC12 and 20 mg/ml 
bovine serum albumin (buffer C) were separately centrifuged at 
10000×g~v for 10 min. Each liposome pellet was then suspended in 
50 lal from the supernatant of the protein solution. The lipid-protein 
mixture was incubated for 1 h at room temperature, and then put on 
ice and incubated for 15 min. The mixture was centrifuged at 
10 000 ×gav for 10 min at 4°C. The supernatant was stored (unbound 
fraction) and the precipitate was washed once with 50 lal of ice-cold 
buffer C. After centrifugation, the supernatant was combined and the 
pellet was suspended with 100 ~tl of the buffer C. The amount of 
protein in each fraction was determined by sandwich ELISA for L- 
MBP or S-MBP using polyclonal antibodies against each protein as 
described above. Liposome binding was defined as (MBPpeltet/ 
MBPr,e]]a+~uporn,tam)×lO0. Control experiments where liposomes 
were deleted from the incubation mixture were also performed. 
2.6. Other methods 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was per- 
formed by the method of Laemmli [19]. Immunoblotting analysis of 
the proteins was carried out using PVDF membranes by a method 
based on that described by Towbin et al. [20]. Amino acid sequences 
of MBPs transferred onto PVDF membranes were determined by an 
Applied Biosystem Model 477A protein sequencer equipped with an 
on-line phenylthiohydantoin (PTH) analyzer (model 120A). Dot blot 
analysis was performed using MBPs and surfactant proteins potted 
onto the nitrocellulose membranes (2 lal of 10 lag/ml protein) to exam- 
ine the specificity of anti-MBP antibody. Protein concentrations were 
estimated by the method of Lowry et al. using bovine serum albumin 
as the standard [21]. 
3. Resu l ts  
3.1. Protein analysis and antibody specificity 
MBPs isolated from serum and liver of rats were analyzed 
by electrophoresis. Serum MBP (S-MBP) and liver MBP (L- 
MBP) showed protein bands at approximately 30 kDa under 
reducing condit ion (Fig. 1A). S-MBP migrated very slightly 
faster than L-MBP. Both S- and L-MBPs form oligomers 
under non-reducing conditions. Under  these conditions, a sig- 
nificant amount  of S-MBP oligomer did not even enter the 
dissolving gel, which is consistent with a previous report that 
S-MBP forms a macromolecule with larger molecular mass 
than L -MBP [4]. The amino-terminal  sequence of S-MBP 
was SGSQTXEE (X: not determined), which was identical 
to Ser l -G lu  s of rat MBP-A described by Drickamer et al. 
[3] and Ikeda et al. [4]. The amino-terminal  sequence of L- 
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Fig. 1. Analysis of MBPs by electrophoresis and immunoblotting. 
Serum MBP (S) and liver MBP (L) were separated on 13% poly- 
acrylamide gel electrophoresis under reducing (+) and under non-re- 
ducing ( - )  conditions, and stained with Coomassie brilliant blue 
(A). Each protein was also transferred onto PVDF membrane and 
immunostained with antibody against each protein using horseradish 
peroxidase-labeled anti-rabbit IgG as the second antibody and dia- 
minobenzidine as the substrate (B). 
MBP was AETLTEG,  which was also identical to Alaa-Gly 7 
of rat MBP-C described by Drickamer et al. [3]. 
Antiserum was prepared against each MBP. Each antibody 
recognized denatured protein by immunoblotting analysis 
(Fig. 1B). Anti-MBP antibodies were also tested to see 
whether they bound to native forms of MBP and other C- 
type lectins by dot blot analysis. Each antibody recognized 
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Fig. 2. Binding of MBPs to various phospholipids coated onto mi- 
crotiter wells. Phosphatidylinositol (PI, t), phosphatidylglycerol 
(PG, • ), phosphatidylserine (PS, II) phosphatidylethanolamine (E2),
egg phosphatidylcholine (z~), dipalmitoylphosphatidylcholine (O), 
and sphingomyelin (0) were coated onto microtiter wells (1 gg 
each lipid/well). The wells were incubated with 0-10 p_g/ml of serum 
MBP (S-MBP) (A) or liver MBP (L-MBP) (B) at room temperature 
for 60 min. The MBP binding to the lipids was detected using anti- 
body (20 pg/ml) against each MBP as described in Section 2. The 
data presented are mean + S.D. (n = 3). 
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Fig. 3. Binding of MBPs to phospholipid liposomes. Multilamellar 
liposomes (100 gg/tube) containing phosphatidylcholine (PC), phos- 
phatidylinositol (PI), phosphatidylserine (PS) and phosphatidylglyc- 
erol (PG) were mixed with 0.2 gg of serum MBP (S-MBP, white 
bars) or liver MBP (L-MBP, hatched bars), and incubated at room 
temperature for 60 min. The MBPs which bound to liposomes were 
sedimented at 10000xg,~,. and the amounts of proteins in the super- 
natant and the pellet were determined by ELISA as described in 
Section 2. The results show specific sedimentation that was deter- 
mined by subtracting values obtained when liposomes were omitted 
(non-specific binding) from total sedimentation. The data shown are 
mean + S.D. (n = 3). 
each MBP and crossreacted with each other, but failed to 
bind surfactant proteins homologous to MBPs (data not 
shown). The results indicate that the anti-MBP antibodies 
obtained are specific for the MBP molecules. 
3.2. Phospholipid binding specificity 
The binding of rat MBPs isolated from serum and liver to 
various phospholipids was examined. S-MBP bound to PI 
coated onto microtiter wells in a concentration-dependent 
manner (Fig. 2A). S-MBP did not bind to phospholipids other 
than PI. L-MBP also bound to PI in a concentration-depend- 
ent manner (Fig. 2B). Unlike S-MBP, L-MBP bound to solid 
phase PG at nearly the level of PI binding. It also bound to 
PS but its binding was approximately one-fourth of P1 bind- 
ing at 10 pg/ml of L-MBP. Co-incubation of anti-MBP anti- 
body with MBPs attenuated the binding of these collectins to 
PI to the level of 5-12°/,, of the control binding at 100 pg/ml of 
antibody concentration. The inclusion of 10 mM EDTA al- 
most completely diminished the binding of MBPs to lipids. 
When the binding of MBPs to lipids was examined in the 
presence of various concentrations of Ca 2+, the proteins ex- 
hibited maximal binding at 2~ mM Ca ~+. Mg 2+ failed to 
replace Ca 2+ for the binding of MBPs to phospholipids. 
3.3. Binding of MBPs to phospholipid liposomes 
We next examined if MBP bound to phospholipid lipo- 
somes, by liposome sedimentation. Twenty-two and 27% of 
S- and L-MBPs, respectively, were co-sedimented with PI lip- 
osomes (Fig. 3). Fifteen or 12% of L-MBP was also co-sedi- 
merited with PG and PS liposomes, respectively. In contrast, 
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the percentages of S-MBPs that co-sedimented with PG and 
PS liposomes were at almost he same level as PC liposomes. 
We also investigated whether excess liposomes competed 
with solid phase phospholipid for MBP binding. 500 ~tM of 
PI liposome competed well with solid phase PI for S-MBP 
binding (Fig. 4A). PI liposome reduced the binding of S- 
MBP to solid phase PI to the level of 22% of the control 
binding. Liposomes composed of PS, PG or PC failed to 
block the S-MBP binding to solid phase PI. PI liposomes 
attenuated the binding of L-MBP to all three phospholipids 
coated onto microtiter wells by 80-86% (Fig. 4B). The binding 
of L-MBP to solid phase PS and PG was blocked when the 
competitor liposome and the solid phase lipid were identical. 
Neither PS liposome nor PG liposome blocked the binding of 
L-MBP to solid phase PG and PS, respectively. These results 
demonstrate hat MBPs are able to bind to phospholipid lip- 
osomes as well as to lipids coated onto microtiter wells. 
3.4. Binding of MBPs to phosphoinositides and 
diphosphatidylglycerol 
Since we had shown that MBPs bind to PI and that L-MBP 
binds to PG, we next examined whether MBPs bound to the 
derivatives of these lipids. Both S- and L-MBPs bound to PIP, 
albeit their bindings were at a level of 40-41% of PI binding 
(Fig. 5). However, the MBPs exhibited nearly negligible bind- 
ing to PIP2. L-MBP bound to diphosphatidylglycerol, cardi- 
olipin. Its binding showed 42% of PG binding. 
3.5. Effect of excess monosaccharides 
We examined whether excess monosaccharides affect the 
binding of MBPs to phospholipids, because MBP belongs to 
C-type lectins. The binding study was performed in the pres- 
ence of 10 or 100 mM of glucose, mannose, inositol, N-ace- 
tylglucosamine or galactose. The binding of S-MBP to PI was 
decreased by the co-incubation with sugars (Table 1). N-Ace- 
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Fig. 4. Competition of phospholipid liposomes with solid phase lip- 
ids for the binding of MBPs. PI (stippled bars), PS (hatched bars) 
and PG (black bars) coated onto microtiter wells (1 ~tg ipid/well) 
were incubated with 10 /ag/ml of S-MBP (A) or L-MBP (B) in the 
absence (cont) or the presence of 500pM phospholipid liposomes 
composed of PI, PS, PG or PC (competitor liposome) at room tem- 
perature for 60 rain. The MBP binding to the solid phase lipids was 
detected using antibody against e ch MBP as described in Section 
2. The results are expressed as percent of control binding. The ab- 
sorbances of the control binding were 1.076_+0.15 (mean _+ S.D., 
n--3) for the S-MBP binding to PI, and 1.067 _+ 0.24 for the L-MBP 
binding to PI, 0.24_+0.039 for the L-MBP binding to PS and 
0.62_+0.10 for the L-MBP binding to PG. The data presented are 
mean _+ S.D. (n = 3). 
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Fig. 5. Binding of MBPs to phosphoinositides and cardiolipin. 
Phosphatidylinositol (PI, white bars), phosphatidylinositol 4-mono- 
phosphate (PIP, stippled bars), phosphatidylinositol 4,5-diphosphate 
(PIP2, light hatched bars), PG (black bars) and cardiolipin (CL, 
dark hatched bars) coated onto microtiter wells (1 ~tg/well) were in- 
cubated with l0 ~tg/ml serum MBP (S-MBP) or liver MBP (L-MBP) 
at room temperature for 60 min. The binding of MBP to the solid 
phase lipids was detected using antibody against e ch MBP as de- 
scribed in Section 2. The data presented are mean + S.D. (n = 3). 
tylglucosamine, glucose, mannose and inositol almost equally 
attenuated the binding of S-MBP to PI, whereas galactose was 
clearly less effective in inhibiting the PI binding. In contrast, 
the inhibitory effects of sugars on the binding of L-MBP to 
three phospholipids were generally less potent han those on 
the binding of S-MBP to PI. Galactose was the most potent 
inhibitor in the monosaccharides t ted for L-MBP binding to 
lipids. 
4. Discussion 
This study provides evidence that phospholipids are novel 
types of ligands for MBPs. Both S- and L-MBPs bound to PI 
and PIP. L-MBP also bound to acidic phospholipids, PG, PS 
and cardiolipin. We have previously shown that the lung sur- 
factant lectins SP-A and SP-D bind to PC and PI, respectively 
[11,12]. The present results raise the possibility that phospho- 
lipids are ligands for collectins. 
The main difficulty in lipid binding studies using microtiter 
wells is that some of the lipids may be washed away through 
the procedures. When [3H]DPPC or various phospholipids 
that had been adsorbed onto microtiter wells were analyzed 
for radioactivity or phosphorus assay, 10-15% of lipids were 
firmly attached to the wells after the washing procedures. 
Previous reports also showed that 10-15%, of glycolipids and 
approximately 30% of phospholipids were firmly attached to 
the wells after the washing procedures [26,27]. The use of 
detergent or its concentration in the washing buffer may affect 
the attachment of the lipids to the wells. In our previous 
studies [9,12], the results obtained from the binding study of 
surfactant proteins to glycolipids and phospholipids coated 
onto microtiter wells corresponded to those done on thin layer 
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Table 1 
Inhibitory activity of various sugars on the binding of MBPs to phospholipids 
391 
Compound Inhibition of binding (%) 
S-MBP L-MBP 
(phospholipids) PI PI PG 
(sugar concentration, raM) 10 100 10 100 10 100 
PS 
I 0 100 
Glucose 18 73 9 40 11 30 32 139 
Mannose 28 70 29 37 40 36 24 35 
Inositol 31 78 21 58 26 62 17 48 
N-Acetylglucosamine 15 78 24 27 19 36 I 1 35 
Galactose 2 21 24 73 48 79 43 66 
The binding of MBPs to phospholipids was carried out in the presence of 10 or 100 mM of various monosaccharides as described in Section 2. The 
results are expressed as % inhibition of binding. The data presented are means of duplicate determinations in two separate xperiments. 
chromatograms. In this study the phospholipid binding spe- 
cificity of MBPs in the solid phase assay was essentially the 
same as that obtained in the liposome binding assay. Thus, 
the method used in this study, at least qualitatively, reflects 
the binding specificity of MBPs to phospholipids. 
Our results showed that the binding of MBPs to PI is Ca 2-- 
dependent. SP-D also binds to PI in a Ca2+-dependent man- 
ner [12]. The possibility is raised that SP-D contaminating the 
MBP preparation may react with PI, since a significant level 
of SP-D is present in the serum of humans with certain lung 
diseases [22]. However, the anti-MBP antibody used in this 
study did not recognize native SP-D. The previous study from 
this laboratory, indicated that SP-D failed to bind PIP [12], 
while both S- and L-MBPs bound to PIP in this study. Taken 
together, we conclude that rat MBPs from serum and liver 
bind to PI, and suggest hat the binding mechanism of MBPs 
to PI may be different from that of SP-D to PI. 
L-MBP bound to acidic phospholipids (PS, PG and cardi- 
olipin) in addition to PI, whereas S-MBP bound exclusively to 
PI. Although the overall structure of the CRD is very similar 
in all C-type lectins, these MBPs exhibit significant differences 
in amino acid sequence despite having 56% identity [3]. Serum 
MBPs such as rat MBP-A and human MBP consist of hex- 
amers of trimeric subunits (M,.~650000) [15]. Liver MBP 
(MBP-C) shows a smaller oligomer (Mr "~ 200 000) [16]. The 
differences of binding specificity between S- and L-MBPs may 
be due to the differences in the primary and oligomeric struc- 
tures. 
L-MBP was found to bind PG, cardiolipin and PS, which 
do not contain sugars. PI liposomes attenuated the binding of 
L-MBP to solid phase PI, PG and PS, while liposomes com- 
posed of PS and PG specifically blocked the binding of L- 
MBP to solid phase PS and PG, respectively, and PS or PG 
liposomes failed to attenuate the binding of L-MBP to solid 
phase PI. One simple explanation for this result is that the 
binding sites 1"o1 PS and PG in the L-MBP molecule may be 
different from each other, and the binding sites for PI may 
straddle the sites for PG and PS when the binding affinity for 
PI is higher than that for PS or PG. However, it remains 
unknown, at present, how L-MBP interacts with these phos- 
pholipids. 
Kozutsumi et al. [I 5] reported that sugar specificity for the 
inhibitory effects on the binding of S-MBP to p25I]mannan 
was similar to that observed on the binding of L-MBP. In this 
study the specificity of monosaccharides for the inhibitory 
effects on S-MBP binding to PI appears different from that 
on L-MBP binding to lipids. Galactose at 100 mM does not 
well inhibit the S-MBP binding to PI but it is the most potent 
inhibitor for L-MBP binding to phospholipids. Thus, these 
results may suggest that the mechanism by which S-MBP 
binds to PI is different from that o1' L-MBP binding to phos- 
pholipids. Although N-acetylglucosamine at 100 mM blocked 
the binding of S-MBP to mannan [15] and to Pi as shown in 
this study, the inhibitory activity by this sugar on the binding 
to Pl is less effective than that on the binding to mannan. This 
difference may be because not only the polar group but also 
the non-polar group of the Pl molecule is involved in the 
binding of S-MBP to PI. 
The annexin family showed binding specificity for acidic 
phospholipids uch as PS and PI [23]. Annexin IV also inter- 
acts with PG [24]. The binding of annexins to phospholipids i
Ca2~-dependent. They bind phospholipids at the micromolar 
range of Ca ~ . In contrast, millimolar Ca e~ is required for 
MBP to bind to lipids as shown in this study. MBP also binds 
PIP or cardiolipin, which have not been reported to have 
phospholipid-binding specificity with the annexins. Thus 
MBPs, like hmg surfactant lectins, are differentiated from 
the annexins, a family of calcium-dependent, phospholipid- 
and membrane-binding proteins. 
S-MBP activates complements through the classical path- 
way to lyse mannan-coated erythrocytes [4]. Human MBP 
also activates the alternative complement pathway and enhan- 
ces serum bactericidal activity on virulent strains ot" Salmonel- 
la [25]. In addition to the carbohydrate binding, the phospho- 
lipid binding property of MBP may also be involved in the 
interaction of this protein with cell membranes, although no 
evidence is available at the moment. The physiological signifi- 
cance of MBP binding to phospholipids remains to be clari- 
fied. The current findings emphasize a novel type of ligand 
binding specificity for MBP. 
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